SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

UCB and Biogen report dapirolizumab pegol response data in lupus study

UCB and Biogen announced further data on the investigational biologic dapirolizumab pegol in systemic lupus erythematosus. The headline reports greater treatment response rates versus placebo using a novel measure.

BIIBUCB

Related stories